EGFR and cancer: Thus, targeted therapies directed at blocking EGFR function are attractive potential therapeutics for cancer.19 Erlotinib, a reversible EGFR tyrosine kinase inhibitor, was initially approved for treatment of patients with advanced NSCLC who had failed one chemotherapy regimen.